PVX 6
Alternative Names: pNGVL4aCRTE6E7L2; pNGVL4aCRTE6E7L2 plasmid DNA; PVX-6Latest Information Update: 10 Aug 2023
At a glance
- Originator PAPIVAX
- Developer PAPIVAX; University of Alabama at Birmingham
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Human papillomavirus infections
Most Recent Events
- 10 Jul 2023 Phase-I clinical trials in Human papillomavirus infections in USA (IM) (NCT03913117)
- 06 Mar 2020 PapiVax Biotech and University of Alabama at Birmingham plans a phase I trial for Human papillomavirus infections in USA in July 2020 (IM, Injection) (NCT03913117)
- 18 Oct 2019 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins plans a phase I trial for Human papillomavirus infections in USA in July 2020 (NCT04131413)